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Objective: Recombinant protective antigen (rPA) is the active pharmaceutical
ingredient of a second generation anthrax vaccine undergoing clinical trials both
in Korea and the USA. By using the rPA produced from Bacillus brevis pNU212
expression system, correlations of serological immune response to anthrax
protection efficacy were analyzed in a guinea pig model.
Methods: Serological responses of rPA anthrax vaccine were investigated in guinea
pigs that were given single or two injections (interval of 4weeks) of various amounts
of rPA combinedwith aluminumhydroxide adjuvant. Guinea pigs were subsequently
challenged by the intramuscular injection with 30 half-lethal doses (30LD50) of
virulentBacillus anthracis spores. Serumantibody titersweredeterminedbyanti-PA
IgGELISAand theabilityof antibodies toneutralize thecytotoxicity of lethal toxinon
J774A.1 cell was measured through the toxin neutralizing antibody (TNA) assay.
Results: To examine correlations between survival rate and antibody titers,
correlation between neutralizing antibody titers and the extent of protection was
determined. Toxin neutralization titers of at least 1176 were sufficient to confer
protection against a dose of 30LD50 of virulent anthrax spores of the H9401 strain.
Such consistency in the correlation was not observed from those antibody titers
determined by ELISA.
Conclusion: Neutralizing-antibody titers can be used as a surrogate marker.1. Introduction
Gram-positive Bacillus anthracis forms highly stable
spores even after excessive UV, heat, or toxic chemical
introductions that affect its survival. Exposure to theseted under the terms of the
) which permits unrestrict
operly cited.
ase Control and Preventionspores by cutaneous, gastrointestinal, or aerosol routes
results in lethal anthrax infection [1]. Poly-D-glutamic
acid capsule and anthrax toxin are the two factors that
are related to the toxicity ofBanthracis in living organism
[2]. The expression of poly-D-glutamic acid capsule,Creative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
. Published by Elsevier Korea LLC. All rights reserved.
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the capsule itself is in charge of protecting bacteria from
the immune system, especially from phagocytosis [2,3].
There are three different protein types of anthrax toxin;
protective antigen (PA), lethal factor (LF), and edema
factor (EF) [4]. These proteins are coded on pX01 plasmid
as pag, lef, and cya genes respectively, and their expres-
sion is under the control of atxA gene [3]. Among these
anthrax toxins, 83 kDa of PA cleaves into 63 kDa as it
attaches to the surface of a host cell, such as a macro-
phage, and becomes a hydrophobic heptamer [4]. LF or
EF binds on this hydrophobic surface to enter the host cell
for expressing own toxicity [5]. When the concentration
of EF, which is a kind of calmodulin-dependent adenylate
cyclase, increases, it raises the concentration of cyclic
adenosine monophosphate [6], and, therefore, chloride
ions and water molecules flow out of the cell body finally
causing edema of the tissue [7]. On the contrary, LF
reduces the mitogen-activated protein kinase signal
transduction and strengthens the level of cytokinesis
tumor necrosis factor-a and interleukin-1b inmacrophage
cells [8]. It also elevates the amount of oxygen radicals [7]
in the host cell resulting in macrophage targeted cyto-
toxicity, which can cause the actual cell and tissue
destruction, and, ultimately, death of the organism.
Interferingwith the binding of PA to LF or EF provides
effective protection from anthrax infection in immunized
animals [9]. Under this concept, the current trend in
developing anthrax vaccine ismainly focused onPA rather
than LF or EF. For example, the anthrax vaccines
approved in theUSAandUKare adsorbed formof purified
PA obtained from the culture supernatant of nontoxigenic
B anthracis [9]. Anthrax Vaccine Adsorbed-Biothrax
(AVA-Biothrax, formerly identified as AVA and
MDPH-PA; BioPort Corporation, Lansing, MI, USA) is
a widely-used anthrax vaccine in the USA which is in
a form of aluminum hydroxide-adsorbed highly purified
recombinant PA (rPA). However, the need for developing
new vaccine is still exist as AVA-Biothrax has some
drawbacks such as partial side-effects in some species and
inconvenience ofmultiple-vaccination to achieve a decent
level of immunization [10].
In this study, adsorbed form of rPA to adjuvant was
tested in a guinea-pig model and their protection rate was
determined to set up a reliable surrogatemarker of anthrax
vaccination. After single or double immunization in
4-week intervals, serum samples from immunized
animals were analyzed and compared to the survival rate
after virulent B anthracis H9401 spore challenge.2. Materials and Methods
2.1. Recombinant PA (rPA) preparation
rPA is purified from culture supernatant of Bacillus
brevis 47-5Q, an asporogenic, avirulent, and non-
toxigenic strain, which contains a recombinant plasmidencoding the PA component of the anthrax toxin [11].
The host B brevis 47-5Q was cultured form modified
PY medium containing proteose peptone (Becton
Dickinson, Sparks, MD, USA) 1%, yeast extract
(Becton Dickinson) 0.5%, uracil 0.01%, glucose 1%,
and 10 mg/ml erythromycin (EM). For the production of
protein, it was grown at 30C in PY broth (containing
proteose peptone 1%, yeast extract 0.5%, uracil 0.01%,
glucose 1%, MgSO4$7H2O 0.01%, FeSO4$7H2O 0.01%,
MnSO4$H2O 0.001%, ZnSO4$7H2O 0.0001%). Unless
otherwise specified, chemicals were obtained from
Sigma (St Louis, MO, USA). Biostat-D DCU2 model
(72 L, B. Braun Biotech International, Germany) was
used as a fermentor for large scale bacteria culture in
high concentration. Bacterial supernatant was filtered by
absolute filter and flowed through anion exchange and
hydrophobic interaction chromatography columns. Ob-
tained protein was tested by SDS-PAGE, western-blot
analysis, and anti-PA specific-ELISA.
2.2. Animals
Female Hartley guinea pigs (300 g to 320 g) were
obtained from Damul Science, Jungeub City, Korea. The
animal procedures were approved by the Institutional
Animal Care and Use Committee of Korea National
Institute of Health.
2.3. Vaccinations and challenge of guinea pigs
Hartley guinea pigs were inoculated intramuscularly
(i.m.) with various concentrations of rPA vaccine
preparation in 0.5 mL volumes as a single injection
(0 week) or as two injections (0 and 4 weeks). rPA was
adsorbed to Alhydrogel (2% Al2O3; Brenntag Biosector,
Frederikssund, Denmark) 250 mg of aluminum per
injection final concentration, for >1 hour at 4C before
use. Blood was collected for serum isolation 3 weeks.
Guinea pigs were challenged in Week 4 after a single or
two injections of vaccine by the i.m. route with a tar-
geted dose of 30 half-lethal doses (30LD50) spore from
B. anthracis H9401. The LD50 of H9401 spores in
Hartley guinea pigs is 50  2 spores [12]. The survival
rates were recorded for 14 days after challenge. Spores
used for the challenge were prepared according to Ivins
et al [13]. Spores used in the experiment were grown in
Leighton and Doi medium [14], purified by centrifuga-
tion through 58% Hypaque-76 (Amersham Health,
Amersham, Buckinghamshire, UK) and suspended in
0.1% gelatin-PBS and stored at 2C to 8C until used.
2.4. Serological assay
2.4.1. Anti-PA IgG ELISA
Serum samples from individual guinea pigs were
analyzed for PA-specific antibody responses using an
enzyme-linked immunosorbent assay (ELISA). Pre-
immune serum obtained 2 days before vaccination was
used as a negative control. The wells of high-binding
microplates (Costar; Corning Inc., Corning, NY, USA)
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buffer (pH 9.5) and incubated for overnight at 4C. The
wells were washed with PBS containing 0.05% (v/v)
Tween 20 (PBST) and blocked with 3% (v/v) bovine
serum albumin in PBST. Serum samples were applied to
the first column of each row and serially diluted with
two-fold volumes of PBST until the last column of the
row and incubated for 1 h at 37C. PA-specific anti-
bodies were detected using a polyclonal goat anti-guinea
pig IgG conjugated to peroxidase (Sigma). After
washing with PBST, color was developed using o-phe-
nylenediamine substrate. The reaction was stopped by
adding 2N H2SO4, and the absorbance at 492 nm was
measured using a Sunrise microplate reader (TECAN
Instruments, Gro¨dig, Austria). The endpoint titers were
defined as the reciprocal of the highest standard serum
dilution that resulted in an absorbance three standard
deviations greater than the average absorbance of
negative control serum samples at the same dilution.
2.4.2. TNA
The titer of toxin-neutralizing antibody in serum was
determined using modifications to the methods of Pitt
et al [15] and Little et al [4] by testing the ability of the
serum to inhibit the cytotoxicity of the combination of
rPA with LF (List Biological Laboratories Inc., Camp-
bell, CA, USA). The assay was carried by exposing
J774A.1 murine macrophages (ATCC TIB-67) to PA
and LF in the presence or absence of serum. In brief,
J774A.1 cells were plated out on 96 well plates (SPL
CO. Ltd, Pyeongtaek-si, Korea) and seeded with 106
cells per well in 150 ml volumes 2 hours before testing.
Cells were maintained in Dulbecco’s minimal essential
medium (DMEM) containing 10% heat-inactivated fetal
bovine serum, 4 mM glutamine, and 25 units of peni-
cillin G and 25 mg of streptomycin/ml (DMEM
complete). Standards and serial two-fold dilutions of
samples were pre-incubated with lethal toxin (LeTx
500 ng of rPA per ml and 100 ng of LF/ml, final
concentrations) in a humidified incubator at 37C, 5%
CO2, for 1 hour. Dilutions of serum sample and LeTx
were prepared in DMEM complete containing 10 mM
HEPES. Medium was removed from wells containing
the J774A.1 cells and replaced with 100 ml per well of
the sample or standard mixed with LeTx. After a 4-hour
incubation at 37C in 5% CO2, 25 ml of 3-[4,5-
dimethylthiazol-2-yl]2,5-diphenyl-tetrazolium bromide
(MTT, Amresco, Solon, OH, USA) was added to each
well at a final concentration of 5 mg/ml. After an
additional 1-hour incubation at 37C, the cells were
lysed by adding 100 ml extraction buffer (90% iso-
propanol containing 25 mM HCl and 0.5% [w/v] SDS).
Absorbance was then measured at 570 nm with an
ELISA reader (Tecan). Each dilution of sample and
standard was tested in duplicate. Six wells contained
only medium and served as medium control. Six LeTx
wells contained only LeTx and served as blanks. Thepercent neutralization (% control) for each dilution of
sample and standard was determined by calculating %
control Z (sample average e lethal toxin avgerage) /
(medium control average e lethal toxin average) 100.
The percent control values were plotted against each
respective test dilution using a four-parameter logistic
equation algorithm and neutralizing antibody titers were
expressed as the reciprocal of the dilution of antiserum
that neutralized the cytotoxic activity of lethal toxin on
J774A.1 cells at 50% of control value (ED50) using
SoftMax Pro 5.3 (Molecular Device, Sunnyvale, CA,
USA).
2.5. Statistical analysis
The correlation between of protection and TNA titer
or anti-PA IgG titers were acquitted with linear regres-
sion analysis was employed. Acceptance criteria include
(1) the R2 for the standard curve had to be 0.95; (2) the
standard curve had to contain at least contiguous stan-
dards; and (3) the coefficient of variation (%CV) for the
duplicate absorbance readings for standards and samples
had to be 20%.
3. Results
3.1. Serological correlate in guinea pigs after
a single injection of rPA vaccine
To determine the efficacy of single vaccination,
guinea pigs were given a single injection with different
amount of rPA adsorbed in Alhydrogel (250 mg in
0.5 mL PBS). Four weeks after immunization, they were
challenged with 30LD50 of B anthracis H9401 spores
(Table 1, Figure 1). Their serum samples were collected
at 4 weeks after immunization, and were analyzed by
anti-PA IgG ELISA and TNA assays to determine their
serological titers. However, reasonable levels of anti-
body titers were not obtained in either assay, hence any
significant relationship between antibody titers and the
actual animal survival rate was not found. These results
also support the clinical study performed by Campbell
et al [16], which demonstrated that a single injection
could not induce any immunological responses in
human volunteers. Taken together with these experi-
mental and clinical evidences, boosting immunization is
necessary for anthrax vaccination to obtain effective
protection.
3.2. Serological correlate in guinea pigs after
two injections of rPA vaccine
To define the serological correlate in guinea pigs with
protection, animals were given different concentrations of
serially diluted rPA vaccines with 250 mg of alhydrogel in
0.5 mL PBS and after 4 weeks they received another shot
of vaccine. Serum samples derived from these animals at
2 week after last vaccination were analysed by anti-PA
IgG titer and TNA assays and their serological titers were
compared with the survival rate (Table 2, Figure 2). In
Table 1. Survival against an i.m. challenge and antibody response of guinea pigs after single injection of rPA vaccine
PA(mg) dose
Survival percentage
(alive/total)
Geometric mean ELISA titer
(standard error)
Geometric mean ED50 TNA
assay titer (standard error)a
50 50 (3/6) 634.96 (1.89) 59.01 (1.27)
25 16.7 (1/6) 400.00 (1.55) 27.41 (1.31)
12.5 0 (0/6) 224.49 (1.45) 18.66 (1.82)
6.3 0 (0/6) 1.0 (1.00) 1.0 (1.00)
3.1 0 (0/6) 1.0 (1.00) 1.0 (1.00)
1.6 0 (0/6) 1.0 (1.00) 1.0 (1.00)
0 (control) 0 (0/6) 1.0 (1.00) 1.0 (1.00)
aED50, reciprocal of the dilution that neutralized 50% of in vitro LeTx cytotoxicity.
Guinea pigs received single i.m. injections (0.5 ml) of rPA vaccine containing various concentrations of rPA. Four weeks later, guinea pigs were challenged
by the i.m. route with a targeted dose of 30LD50 spores of the B anthracis H9401 strain. Sera were tested in a anti-PA IgG Titer and TNA assay.
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increase after the second injection and the overall titers
were much higher compared to those from single immu-
nization. And increasing tendency of serological titers
with higher concentration of rPA and the survival rate was
observed (Tables 1 and 2). Furthermore, 100% of animals
survived with 50 mg of rPA per dose in 4-week double
immunizations, which did not happen with any of the
experimental group with single immunization. TheseFigure 1. Relationship between survivals of guinea pig with
a single injection of rPA vaccine after i.m. challenge with B
anthracis H9401 spore and Week 3. (A) Anti-PA IgG titer, (B)
ED50 TNA assay. Guinea pigs (C) surviving or (B) dying
after i.m. injection.results clearly support the classical immunological
concept that the boosting brings higher protection rate to
challenge [17].
3.3. Serological titer from double vaccination
produces a reliable coefficient to survival
rates
To obtain correlate between serological titers and
protection, serological titers of serum samples from
individual animals were compared to the survival data
and linear regression analysis was performed to obtain
R2 values. Among two serological titers, anti-PA IgG
titers from the animals of 4 week double immunization
schedule did not show any correlation to the survival
rate under this experimental condition (R2 Z 0.18, data
not shown). On the contrary, a high correlation coeffi-
cient was obtained from TNA titers with serum samples
of double immunizations (R2 Z 0.96) (Figure 3). From
the linear regression analysis, TNA titers for 50%
survival against 30LD50 spore challenge was 551 and for
100% survival was 1176. The correlation coefficient
ensured that double immunization schedule with a 4-
week interval might be able to give a good indication
about vaccine efficacy. This also partially supports the
previous finding that asserted admitting TNA as
a surrogate marker for testing vaccine efficacy [18].
4. Discussion
The correlation between neutralizing-antibody titers
and protection against B anthracis infection in different
animal species vaccinated with rPA provides surrogate
markers to evaluate the protective efficiency of rPA
vaccines in humans [19e27]. Because of the cost
associated with conducting such studies with a large
enough number of nonhuman primates to achieve
statistically significant results, alternative animal models
have been examined. McBride et al [26] were unable to
identify a correlate of protection in guinea pigs that had
received three inoculations of rPA (250, 2.5, 0.25, or
0.025 mg/dose) formulated with Alhydrogel adjuvant at
Table 2. Survival against an i.m. challenge and antibody response of guinea pigs after two injections of rPA vaccine
PA (㎍) dose
Survival percentage
(alive/total)
Geometric mean
ELISA titer (standard
error)
Geometric mean ED50
TNA assay titer
(standard error)a
50 100 (9/9) 43890.9 (1.12) 4063.8 (1.26)
25 100 (9/9) 25600.0 (1.22) 3225.4 (1.26)
12.5 88.9 (8/9) 16126.9 (1.29) 1097.3 (1.35)
6.3 80.0 (8/10) 5198.4 (1.26) 685.9 (1.18)
3.1 33.3 (3/9) 696.4 (1.72) 278.6 (1.38)
1.6 30.0 (3/10) 459.5 (1.09) 113.1 (1.37)
0 (Control) 0.0 (0/10) 1.0 (1.00) 1.0 (1.00)
aED50, reciprocal of the dilution that neutralized 50% of in vitro LeTx cytotoxicity.
Guinea pigs received two i.m. injections at 0 and 4 weeks (0.5 ml each) of rPA vaccine containing various concentrations of rPA. Four weeks after the last
injection (Week 8), guinea pigs were challenged by the i.m. route with a targeted dose of 30LD50 spores of the B. anthracis H9401 strain. Sera were tested in
a anti-PA IgG Titer and TNA assay.
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aerosol route with the Ames strain of B anthracis. Pitt
et al [27] reported that survival of guinea pigs that had
been challenged 3 months after being inoculated with
two injection of rPA (50, 5, or 0.5 mg/dose) formulated
with alhydrogel at 0 and 4 weeks was not dose depen-
dent. Reuveny et al [18] argued against multipleFigure 2. Relationship between survivals of guinea pig
inoculated with two injection of rPA vaccine after i.m. chal-
lenge with B. anthracis H9401 spore and Week 7. (A) Anti-PA
IgG titer; (B) ED50 TNA assay. Guinea pigs (A) surviving or
(>) dying after i.m. injection.inoculations and favored a single inoculation of vaccine.
Their group demonstrated that their neutralizing anti-
body titers could serve as an effective correlate of
protection for guinea pigs that were challenged intra-
dermally with spores of the Vollum strain spore of B
anthracis after a single subcutaneous inoculation of rPA
(25, 12.5, 6.3, 3.1, 1.6, or 0.8 mg) adsorbed to Alhy-
drogel. The anti-PA IgG titers, however, proved to be of
limited value in serving as a surrogate marker [18].
Our present study was designed to find correlations
between protection level and either anti-PA IgG IgG
titers or neutralizing-antibody titers. To eliminateFigure 3. Correlation between TNA titers and protection
after two injections. Relationship between serological titer and
protection of guinea pigs with a double vaccination serially
diluted of rPA vaccine at a 4-week interval. After 4 weeks after
the second vaccination, guinea pigs were challenged i.m with
B anthracis H9401 spores. Each point in the group represents
the average of duplicate determinations performed with pooled
sera derived from 9 or 10 guinea pigs. TNA titers of serum
samples from individual animals in each group were compared
to the survival data of the animals (inset). Linear regression
was performed using data from experimental cohorts with
neutralizing-antibody titers of 1176 or less. The calculated R2
value is 0.96.
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nents, we have used highly purified rPA adsorbed to
alhydrogel as a vaccine. For the first step of establishing
a surrogate marker for anthrax vaccine, suitable immu-
nization intervals (4 week) were determined (data not
shown). Then we tested the number of vaccinations to
obtain adequate level of protection efficacy for testing
rPA-alhydrogel vaccine. In the case of the single
injection experiment, we obtained just 50% protection
with the highest rPA dose and antibody titers were not
high enough to guarantee the reproduction of this result,
especially in TNA (titers < 100). Because of these
reasons, single injection was not the optimal condition
to examine vaccine efficacy.
With the information that a single injection is not
sufficient to establish serological marker, we performed
another set of experiments using two injections with a 4-
week interval. In this case, it would obviously obtain
higher serological titers in both assays compared to
those of single injection schedule. Overall, animals that
received two injections could survive more than animals
with single injection and serological titers rapidly
increased after the second injection. These results
clearly support the classical concept that boosting brings
higher serological titer and a higher protection rate to
immunological challenge [17]. We could obtain rela-
tively high correlation coefficients from anti-PA IgG
and neutralizing-antibody titers with serum samples
from 4 weeks injection schedule (R2 Z 0.18 in anti-PA
IgG ELISA, R2 Z 0.96 in TNA). These correlation
coefficients ensured that a two-injection schedule with
a 4 week interval might be able to serum as a good
surrogates about vaccine efficacy.
Our findings support the notion that antibodies
involved in neutralization are also involved in protection
against the full course of infection. This is in agreement
with previous observations in which monoclonal anti-
bodies capable of neutralizing the cytotoxic effect were
shown to delay death in guinea pigs [28]. The results
indicate that neutralizing-antibody titers can be used as
a reliable correlate for protection in guinea pigs. A
correlation between protection and neutralization titers
was recently observed in a rabbit model [15], suggesting
that this phenomenon is not species specific. Application
of such markers to human studies therefore appears to be
feasible, even though similar experiments in nonhuman
primates would be required to gain more confidence.
In conclusion, we have produced a series of experi-
mental data to establish a surrogate marker that can
indicate rPA vaccine efficacy. According to our results,
the best correlation between serological titers and animal
survival rates was obtained with double immunization
using a 4-week interval schedule. Under this condition,
antibody titers obtained by TNA were high enough to be
reproduced and R2 values higher than 0.95, which indi-
cates that TNA can be a reliable experimental technique
for estimating animal survival. Therefore, to test theefficacy of an anthrax PA vaccine, two injections in
combination of appropriate adjuvant at a 4-week interval
and TNA for serological assay are recommended.Acknowledgements
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